US-based pharmaceutical company Reviva Pharmaceuticals has reported positive topline data from its Phase III RECOVER clinical trial of brilaroxazine in adult patients with schizophrenia.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,